{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=39&q=fallopian+tube",
    "query": {
      "q": "fallopian tube",
      "condition": "Ovarian Cancer",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 739,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=40&q=fallopian+tube&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=38&q=fallopian+tube&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T04:21:30.598Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05053750",
      "title": "TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian",
        "Fallopian Tube",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel/Bev (control)",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel/Bev + ZA (experimental)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2021-12-14",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053750"
    },
    {
      "nct_id": "NCT00005025",
      "title": "Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "herpes simplex thymidine kinase",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "John Stoddard Cancer Center at Iowa Methodist Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-06",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 1,
      "location_summary": "Des Moines, Iowa",
      "locations": [
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005025"
    },
    {
      "nct_id": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Unresectable Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Non-Small Cell Lung Cancer Squamous",
        "Non-Small Cell Lung Cancer Non-squamous",
        "Colorectal Cancer (MSI-H)",
        "Gastric Cancer",
        "Cervical Cancer",
        "Basal Cell Carcinoma",
        "Bladder Cancer",
        "Merkel Cell Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cutaneous Squamous Cell Carcinoma",
        "Pleural Mesothelioma",
        "Esophageal Cancer",
        "Endometrial Carcinoma",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "MSI-H Solid Malignant Tumor",
        "Cancer With A High Tumor Mutational Burden",
        "Epithelial Ovarian Carcinoma",
        "Primary Peritoneal Cancer",
        "Gastroesophageal Junction (GEJ) Cancer",
        "Acral Melanoma",
        "Mucosal Melanoma",
        "Cutaneous Melanoma",
        "DMMR Solid Malignant Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "MSI-H Cancer",
        "DMMR Cancer",
        "Pancreas Adenocarcinoma (MSI-H)",
        "Skin Cancer",
        "Viral Cancer",
        "Cervical Cancers",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "MDNA11",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicenna Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2021-08-27",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 7,
      "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05086692"
    },
    {
      "nct_id": "NCT00003944",
      "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3,
      "start_date": "1998-08",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2013-04-17",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003944"
    },
    {
      "nct_id": "NCT01544049",
      "title": "Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2011-12",
      "completion_date": "2018-09-04",
      "has_results": false,
      "last_update_posted_date": "2018-09-12",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01544049"
    },
    {
      "nct_id": "NCT00899093",
      "title": "YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Malignant Ovarian Brenner Tumor",
        "Malignant Ovarian Clear Cell Tumor",
        "Malignant Ovarian Endometrioid Tumor",
        "Malignant Ovarian Mixed Epithelial Tumor",
        "Malignant Ovarian Mucinous Tumor",
        "Malignant Ovarian Neoplasm",
        "Malignant Ovarian Serous Tumor",
        "Malignant Ovarian Transitional Cell Tumor",
        "Ovarian Adenocarcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Undifferentiated Fallopian Tube Carcinoma",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2500,
      "start_date": "2007-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 131,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00899093"
    },
    {
      "nct_id": "NCT02595892",
      "title": "Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Serous Tumor",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2016-08-25",
      "completion_date": "2027-08-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595892"
    },
    {
      "nct_id": "NCT03213964",
      "title": "Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "FATE-NK100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2017-10-19",
      "completion_date": "2021-03-10",
      "has_results": false,
      "last_update_posted_date": "2021-03-12",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213964"
    },
    {
      "nct_id": "NCT01275664",
      "title": "Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nausea and Vomiting",
        "Ovarian Brenner Tumor",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Stage II Ovarian Cancer",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adjuvant Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Granisetron Transdermal Patch",
          "type": "DRUG"
        },
        {
          "name": "Management of Therapy Complications",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2011-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 2,
      "location_summary": "Hinsdale, Illinois • Providence, Rhode Island",
      "locations": [
        {
          "city": "Hinsdale",
          "state": "Illinois"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275664"
    },
    {
      "nct_id": "NCT04701645",
      "title": "Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Ovarian Cancer Stage III",
        "Ovarian Cancer Stage IV",
        "Fallopian Tube Cancer Stage IV",
        "Fallopian Tube Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "Microdevice",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2022-11-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-16T04:21:30.598Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701645"
    }
  ]
}